TP53 and cancer: SPIA revealed five significantly perturbed (p <0.01) pathways, including two activated (“small cell lung cancer” and “pathways in cancer”) and three inhibited pathways (“direct p53 effectors”, “mcalpain and friends in cell motility”, and “a6b1 and a6b4 integrin signaling”; Additional file 3: Table S3).